✨ Free AI Report
Zealand Pharma A/S: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Zealand Pharma A/S
Company Research

Zealand Pharma A/S: Business Overview, Financials & Competitive Analysis

Zealand Pharma A/S scores 8/10 on the AskCyborg Cyborg Score (Strong). Partnership-driven biotech with obesity blockbuster potential and multiple 2026 clinical/regulatory catalysts positioned for significant value creation. Zealand is eligible for potential milestones from Roche of USD 700 million in 2026, including a development milestone of USD 575 million and an anniversary payment of USD 125 million. The company completed.

What is Zealand Pharma A/S's industry? Zealand Pharma A/S (zealandpharma.com) operates in Biotechnology - Specialty Pharma (Obesity & Metabolic Health). AskCyborg classifies Zealand Pharma A/S under Biotechnology - Specialty Pharma (Obesity & Metabolic Health) in its company registry.

Zealand Pharma is a biotechnology company engaged in discovery, development, and commercialization of peptide-based medicines focusing on gastrointestinal and metabolic diseases. The company maintains a portfolio with...

8/ 10Strong

Cyborg Score thesis

Partnership-driven biotech with obesity blockbuster potential and multiple 2026 clinical/regulatory catalysts positioned for...

Read the full analyst-debate transcript →
Industry Biotechnology - Specialty Pharma (Obesity & Metabolic Health)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Zealand Pharma A/S Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Zealand Pharma A/S

AskCyborg analysts argue the bull and bear cases for Zealand Pharma A/S across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Zealand Pharma A/S OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Zealand Pharma A/S Overview

Pro stress-test →

Zealand Pharma is a biotechnology company engaged in discovery, development, and commercialization of peptide-based medicines focusing on gastrointestinal and metabolic diseases. The company maintains a portfolio with commercial products and multiple candidates in late-stage development aimed at addressing unmet medical needs.

Strategic Profile

Pro stress-test →

Unlike many small biotechs, Zealand utilizes a partnership model to mitigate risk and maximize distribution. The company entered a transformative collaboration with Roche to co-develop and co-commercialize petrelintide, aiming to redefine the standard of care for people with overweight and obesity by establishing the leading amylin-based franchise around petrelintide.

Competitive Landscape

Pro stress-test →

Zealand has gained substantial attention due to its promising pipeline positioning it as a key competitor in the GLP-1 and weight-loss space. Compared to peers, Zealand is viewed as more agile and R&D-focused than diversified giants, lacking the massive current revenue of Eli Lilly but offering specialized focus on next-generation peptides.

Industry Context

Zealand Pharma A/S operates in Biotechnology - Specialty Pharma (Obesity & Metabolic Health).

Key facts

Founded: 1997 · Headquarters: Søborg, Denmark · Employees: 481 · Revenue: $1.44B · Market cap: $3.46B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Zealand Pharma A/S.

  • Historic Roche partnership for petrelintide represents a transformative collaboration for obesity treatment.
  • Petrelintide Phase 2 enrollment complete with 42-week topline data expected Q1 2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Zealand announces record 2025 revenue driven by Roche partnership and multiple clinical milestones.
  • February 2026Positive Phase 1a topline results reported for ZP9830 Kv1.3 channel blocker in chronic inflammation.
  • +1 moreTrack every material event for Zealand Pharma A/S as it happens. Explore monitoring →
Get alerted when Zealand Pharma A/S has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GLP-1 receptor agonistsEstablished obesity/diabetes treatments→Tirzepatide (Mounjaro/Zepbound)GLP-1/GIP dual agonist obesity therapy→SaxendaGLP-1 agonist for weight management→

Compare Zealand Pharma A/S with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Zealand Pharma A/S operates in Biotechnology - Specialty Pharma (Obesity & Metabolic Health). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Specialty Pharma (Obesity & Metabolic Health) research →
NEW · MCP server

Ask your AI assistant about Zealand Pharma A/S

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Zealand Pharma A/S and its top competitor on Cyborg Score”
“What did Zealand Pharma A/S do this quarter?”
“Is Zealand Pharma A/S a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Zealand Pharma A/S do?+
Zealand Pharma is a biotechnology company engaged in discovery, development, and commercialization of peptide-based medicines focusing on gastrointestinal and metabolic diseases. The company maintains a portfolio with...
What is Zealand Pharma A/S's Cyborg Score?+
Zealand Pharma A/S has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Zealand Pharma A/S's main competitors?+
Named competitors include GLP-1 receptor agonists, Tirzepatide (Mounjaro/Zepbound), Saxenda. The full competitive landscape is in the AskCyborg report.
How can I get the full Zealand Pharma A/S research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Zealand Pharma A/S research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Zealand Pharma A/S over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.